# Avalyn Pharma Inc.: overview AVLN · Nasdaq · CIK 1540171 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/avln.md) · [Financials](/companies/avln/financials.md) · [Filings](/companies/avln/filings.md) · [Insiders](/companies/avln/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(63.24)](/filings/0001193125-26-254623.md) | [(17.63)](/filings/0001193125-26-345820.md) | [(21.83)](/filings/0001193125-26-254623.md) | [(0.98)](/filings/0001193125-26-345820.md) | | Free cash flow | $m | [(19.3)](/filings/0001193125-26-254623.md) | [(20.7) d](/filings/0001193125-26-345820.md) | [(30.2)](/filings/0001193125-26-254623.md) | [(26.3) d](/filings/0001193125-26-345820.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure. ## Last five fiscal years Not reported. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/avln/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $192.1m | 5,835,259 | | New +5,835,259 | | [NOVO HOLDINGS A/S](/funds/1388325.md) | 2026-06-30 | $127.8m | 3,883,289 | | New +3,883,289 | | [SR One Capital Management, LP](/funds/1910264.md) | 2026-06-30 | $108.9m | 3,308,649 | | New +3,308,649 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $88.1m | 2,675,296 | | New +2,675,296 | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $82.4m | 2,503,109 | | New +2,503,109 | | [NVP ASSOCIATES, LLC](/funds/1545692.md) | 2026-06-30 | $74.7m | 2,268,404 | | New +2,268,404 | | [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $72.5m | 2,201,986 | | New +2,201,986 | | [Catalio Capital Management, LP](/funds/1958125.md) | 2026-06-30 | $55.2m | 1,675,830 | | New +1,675,830 | | [EVENTIDE ASSET MANAGEMENT, LLC](/funds/1442891.md) | 2026-06-30 | $45.3m | 1,375,486 | | New +1,375,486 | | [Bellevue Group AG](/funds/1674546.md) | 2026-06-30 | $44.4m | 1,350,000 | | New +1,350,000 | ## Recent filings [All 63 filings](/companies/avln/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-16 | 16:13 ET | [8-K](/filings/0001193125-26-393081.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-393081 | | 2026-08-12 | 08:15 ET | [10-Q](/filings/0001193125-26-345820.md) | Quarterly report, period 2026-06-30 | 0001193125-26-345820 | | 2026-08-12 | 08:06 ET | [8-K](/filings/0001193125-26-345807.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-345807 | | 2026-07-01 | 17:20 ET | [8-K](/filings/0001193125-26-292834.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-292834 | | 2026-06-17 | 08:03 ET | [8-K](/filings/0001193125-26-273405.md) | 7.01 Regulation FD disclosure | 0001193125-26-273405 | | 2026-06-03 | 08:00 ET | [10-Q](/filings/0001193125-26-254623.md) | Quarterly report, period 2026-03-31 | 0001193125-26-254623 | | 2026-06-03 | 07:25 ET | [8-K](/filings/0001193125-26-254581.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-254581 | | 2026-05-08 | 18:52 ET | [SCHEDULE 13D](/filings/0000899140-26-000428.md) | Ownership report, active investor | 0000899140-26-000428 | | 2026-05-08 | 16:41 ET | [SCHEDULE 13D](/filings/0001072613-26-000386.md) | Ownership report, active investor | 0001072613-26-000386 | | 2026-05-01 | 16:09 ET | [8-K](/filings/0001193125-26-201434.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-201434 | ## Latest annual report No annual report is in coverage. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1540171 - Tickers: AVLN - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.